Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

BAGSVÆRD, Denmark - Novo Nordisk (NYSE:NVO), a global healthcare company, has announced its agreement to purchase Cardior Pharmaceuticals for up to €1.025 billion, which ...

Please provide your email address to receive an email when new articles are posted on . Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging ...

After a successful and dynamic transition process following Cardior’s acquisition by Novo Nordisk, I will be stepping down as CEO of Cardior Pharmaceuticals. This journey has been incredible ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.